Guidant's Response to Form 483 Emphasizes Part 11 Controls

Devices & Diagnostics Letter
KEYWORDS 483 / Part 11

Although Guidant disagreed with the FDA’s recent observation of apparent software validation and electronic records control violations, the company said it would examine and strengthen the relevant in-house requirements and implementation guidelines to ensure compliance with 21 CFR Part 11.

To View This Article:


Buy This Article Now

Add this article to your cart for $10.00